|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bristow RE: Surgical standards in the
management of ovarian cancer. Curr Opin Oncol. 12:474–480. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Harries M and Gore M: Part II:
Chemotherapy for epithelial ovarian cancer-treatment of recurrent
disease. Lancet Oncol. 3:537–545. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Trimble EL, Wright J and Christian MC:
Treatment of platinum-resistant ovarian cancer. Expert Opin
Pharmacother. 2:1299–1306. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen L, Cheng X, Tu W, Qi Z, Li H, Liu F,
Yang Y, Zhang Z and Wang Z: Apatinib inhibits glycolysis by
suppressing the VEGFR2/AKT1/SOX5/GLUT4 signaling pathway in ovarian
cancer cells. Cell Oncol (Dordr). 42:679–690. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Alvarez-Garcia I and Miska EA: MicroRNA
functions in animal development and human disease. Development.
132:4653–4662. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ma J, Li Y, Yao L and Li X: Analysis of
MicroRNA expression profiling involved in MC-LR-induced
cytotoxicity by high-throughput sequencing. Toxins (Basel).
9:E232017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ma J and Li X: High-throughput sequencing
provides an insight into the hepatotoxicity mechanism of MC-LR in
HepG2 cells. Toxin Reviews. 37:1–10. 2017. View Article : Google Scholar
|
|
11
|
Zhang L, Volinia S, Bonome T, Calin GA,
Greshock J, Yang N, Liu CG, Giannakakis A, Alexiou P, Hasegawa K,
et al: Genomic and epigenetic alterations deregulate microRNA
expression in human epithelial ovarian cancer. Proc Natl Acad Sci
USA. 105:7004–7009. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Iorio MV, Visone R, Di Leva G, Donati V,
Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et
al: MicroRNA signatures in human ovarian cancer. Cancer Res.
67:8699–8707. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Davidson B, Tropé CG and Reich R: The
clinical and diagnostic role of microRNAs in ovarian carcinoma.
Gynecol Oncol. 133:640–646. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xu YZ, Xi QH, Ge WL and Zhang XQ:
Identification of serum microRNA-21 as a biomarker for early
detection and prognosis in human epithelial ovarian cancer. Asian
Pac J Cancer Prev. 14:1057–1060. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cappellesso R, Tinazzi A, Giurici T,
Simonato F, Guzzardo V, Ventura L, Crescenzi M, Chiarelli S and
Fassina A: Programmed cell death 4 and microRNA 21 inverse
expression is maintained in cells and exosomes from ovarian serous
carcinoma effusions. Cancer Cytopathol. 122:685–693. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xie Z, Cao L and Zhang J: miR-21 modulates
paclitaxel sensitivity and hypoxia-inducible factor-1α expression
in human ovarian cancer cells. Oncol Lett. 6:795–800. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yokoi A, Matsuzaki J, Yamamoto Y, Yoneoka
Y, Takahashi K, Shimizu H, Uehara T, Ishikawa M, Ikeda SI, Sonoda
T, et al: Integrated extracellular microRNA profiling for ovarian
cancer screening. Nat Commun. 9:43192018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu W, Yue F, Zheng M, Merlot A, Bae DH,
Huang M, Lane D, Jansson P, Lui GY, Richardson V, et al: The
proto-oncogene c-Src and its downstream signaling pathways are
inhibited by the metastasis suppressor, NDRG1. Oncotarget.
6:8851–8874. 2015.PubMed/NCBI
|
|
19
|
Fang D, Chen H, Zhu JY, Wang W, Teng Y,
Ding HF, Jing Q, Su SB and Huang S: Epithelial-mesenchymal
transition of ovarian cancer cells is sustained by Rac1 through
simultaneous activation of MEK1/2 and Src signaling pathways.
Oncogene. 36:1546–1558. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Le XF and Bast RC Jr: Src family kinases
and paclitaxel sensitivity. Cancer Biol Ther. 12:260–269. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang LQ, Lv RW, Qu XD, Chen XJ, Lu HS and
Wang Y: Aloesin suppresses cell growth and metastasis in ovarian
cancer SKOV3 cells through the inhibition of the MAPK signaling
pathway. Anal Cell Pathol (Amst). 2017:81582542017.PubMed/NCBI
|
|
22
|
Kennedy S, Clynes M, Doolan P, Mehta JP,
Rani S, Crown J and O'Driscoll L: SNIP/p140Cap mRNA expression is
an unfavourable prognostic factor in breast cancer and is not
expressed in normal breast tissue. Br J Cancer. 98:1641–1645. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gregoire L, Rabah R, Schmelz EM, Munkarah
A, Roberts PC and Lancaster WD: Spontaneous malignant
transformation of human ovarian surface epithelial cells in vitro.
Clin Cancer Res. 7:4280–4287. 2001.PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fogh J, Wright WC and Loveless JD: Absence
of HeLa cell contamination in 169 cell lines derived from human
tumors. J Natl Cancer Inst. 58:209–214. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pal MK, Jaiswar SP, Dwivedi VN, Tripathi
AK, Dwivedi A and Sankhwar P: MicroRNA: A new and promising
potential biomarker for diagnosis and prognosis of ovarian cancer.
Cancer Biol Med. 12:328–341. 2015.PubMed/NCBI
|
|
27
|
Li C, Duan P, Wang J, Lu X and Cheng J:
miR-320 inhibited ovarian cancer oncogenicity via targeting TWIST1
expression. Am J Transl Res. 9:3705–3713. 2017.PubMed/NCBI
|
|
28
|
Xu Y, Hu J, Zhang C and Liu Y: MicroRNA320
targets mitogenactivated protein kinase 1 to inhibit cell
proliferation and invasion in epithelial ovarian cancer. Mol Med
Rep. 16:8530–8536. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tan H, Zhao L, Song R, Liu Y and Wang L:
microRNA-665 promotes the proliferation and matrix degradation of
nucleus pulposus through targeting GDF5 in intervertebral disc
degeneration. J Cell Biochem. 119:7218–7225. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dong C, Du Q, Wang Z, Wang Y, Wu S and
Wang A: MicroRNA-665 suppressed the invasion and metastasis of
osteosarcoma by directly inhibiting RAB23. Am J Transl Res.
8:4975–4981. 2016.PubMed/NCBI
|
|
31
|
Samatar AA and Poulikakos PI: Targeting
RAS-ERK signalling in cancer: Promises and challenges. Nat Rev Drug
Discov. 13:928–942. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yu Z, Ye S, Hu G, Lv M, Tu Z, Zhou K and
Li Q: The RAF-MEK-ERK pathway: Targeting ERK to overcome obstacles
to effective cancer therapy. Future Med Chem. 7:269–289. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen R, Liao JY, Huang J, Chen WL, Ma XJ
and Luo XD: Downregulation of SRC kinase signaling inhibitor 1
(SRCIN1) expression by MicroRNA-32 promotes proliferation and
epithelial-mesenchymal transition in human liver cancer cells.
Oncol Res. 26:573–579. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xu X, Wang W, Su N, Zhu X, Yao J, Gao W,
Hu Z and Sun Y: miR-374a promotes cell proliferation, migration and
invasion by targeting SRCIN1 in gastric cancer. FEBS Lett.
589:407–413. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang F, Luo LJ, Zhang L, Wang DD, Yang SJ,
Ding L, Li J, Chen D, Ma R, Wu JZ and Tang JH: miR-346 promotes the
biological function of breast cancer cells by targeting SRCIN1 and
reduces chemosensitivity to docetaxel. Gene. 600:21–28. 2017.
View Article : Google Scholar : PubMed/NCBI
|
